SCHEMBL2325474

SCHEMBL2325474

COP(=O)(CC(=O)c1cn(Cc2ccccc2)nc1C)OC

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 4/20 0.47
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 2/20 0.43
SCD O00767 2/20 0.43
LMNA P02545 1/20 0.43
FFAR4 Q5NUL3 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
PARP1 P09874 1/20 0.40
KLK1 P06870 2/20 0.39
MAPK1 P28482 1/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 3/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
EGLN1 Q9GZT9 2/20 0.38
DGAT1 O75907 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2325482 0.82 KLKB1 (0.45) KLKB1KMT2AALDH1A1SCDLMNA
SCHEMBL720425 0.79 KLKB1 (0.53) KLKB1KMT2AALDH1A1SCDLMNA
SCHEMBL6052401 0.79 ALDH1A1 (0.56) KLKB1KMT2AALDH1A1SCDLMNA
SCHEMBL14343418 0.77 KLKB1 (0.53) KLKB1KMT2AALDH1A1SCDLMNA
SCHEMBL2328757 0.77 GAA (0.44) KMT2AALDH1A1POLBMEN1NPC1
SCHEMBL5733127 0.77 KLKB1 (0.47) KLKB1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL20798456 0.76 KLKB1 (0.52) KLKB1KMT2AALDH1A1SCDLMNA
SCHEMBL2325459 0.76 SMN1; SMN2 (0.48) KMT2AALDH1A1LMNAMAPK1POLB
Hydrochloric Acid SCHEMBL6319641 0.71 KLKB1 (0.55) KLKB1KMT2AALDH1A1SCDLMNA
SCHEMBL259686 0.70 HDAC1 (0.48) KLKB1ALDH1A1SCDLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 KLKB1 336/4885KMT2A 2891/4885ALDH1A1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.